Abbvie CDR (ABBV) News

AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases

AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases PR Newswire NORTH...

SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator

SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore...

European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

AbbVie Completes Acquisition of Cerevel Therapeutics

AbbVie Completes Acquisition of Cerevel Therapeutics PR Newswire NORTH CHICAGO, Ill., Aug. 1, 2024 Cerevel's clinical-stage assets complement...

Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day

Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day PR Newswire IRVINE, Calif., July 30, 2024 Join the seven million loyal Allē...

Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots

Toyota Motor (NYSE:TM) – Toyota’s global production fell 12.9% in June to 795,862 vehicles...

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in...

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with...

Form 8-K - Current report

AbbVie Reports Second-Quarter 2024 Financial Results

AbbVie Reports Second-Quarter 2024 Financial Results PR Newswire NORTH CHICAGO, Ill., July 25, 2024 Reports...

U.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire Expectations

U.S. index futures are mixed in pre-market trading on Thursday following a sharp tech sector sell-off the...